ArticleBreast cancer research and treatment2026
Age-dependent relative and absolute benefit of radiotherapy after breast-conserving surgery: a population-based analysis using SEER data.
Article in Breast cancer research and treatment, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRadiotherapy (RT) after breast-conserving surgery (BCS) improves breast cancer outcomes. However, its clinical relevance may vary with age, particularly in the presence of competing risks and treatment burden. How the association between RT and breast cancer-specific survival changes across the age spectrum has not been well characterized.
methodsPatients aged ≥ 50 years who underwent BCS for breast cancer were identified from the SEER database between 2000 and 2022. Patients with unknown or refused RT status, unknown cause of death, or follow-up < 3 months were excluded. Inverse probability of treatment weighting (IPTW)-adjusted Cox proportional hazards models with age-by-treatment interaction terms were used to estimate age-specific associations between RT and breast cancer-specific survival (BCSS). Absolute effects were assessed using cumulative incidence functions accounting for competing risks, and continuous age effects were evaluated using restricted cubic spline models.
resultsAmong 532,118 eligible patients, 409,652 (77.0%) received RT and 122,466 (23.0%) did not. RT was associated with improved BCSS across all age groups. The relative association attenuated with increasing age, with hazard ratios increasing from 0.54 (95% CI, 0.51-0.58) among patients aged 50-54 years to 0.81 (95% CI, 0.75-0.88) among those aged ≥ 85 years (p for interaction < 0.001). Absolute risk reduction also decreased with age, from approximately 5.2-5.6% in younger patients to 2.9-3.7% in patients aged 70-84 years. Restricted cubic spline analysis showed a gradual attenuation of the RT-associated survival advantage with age, without evidence of an abrupt threshold.
conclusionsRT after BCS was associated with improved BCSS across the age spectrum, although both relative and absolute benefits became smaller with increasing age. These findings support individualized treatment decisions that consider absolute benefit, competing risks, and patient-specific factors rather than relying only on fixed age thresholds.
Indexed as
Identifiers
42493682What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.